Health
Cardiovascular effects of the post-COVID-19 condition
Yuki, K., Fujiogi, M. & Koutsogiannaki, S. COVID-19 pathophysiology: a review. Clin. Immunol. 215, 108427 (2020).
Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023). This comprehensive review of long COVID highlights important underlying pathophysiology and includes detailed information on both cardiac and noncardiac effects of this condition.
Thaweethai, T. et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA https://doi.org/10.1001/jama.2023.8823 (2023).
Bonilla, H. et al. Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front. Immunol. 14, 1129459 (2023).
Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210–216 (2022).
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324, 782–793 (2020).
Long, B. et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am. J. Emerg. Med. 54, 46–57 (2022).
Tsampasian, V. et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern. Med. 183, 566–580 (2023).
Dessie, Z. G. & Zewotir, T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect. Dis. 21, 855 (2021).
Lundberg, D. J. et al. COVID-19 mortality by race and ethnicity in US metropolitan and nonmetropolitan areas, March 2020 to February 2022. JAMA Netw. Open 6, e2311098 (2023).
Minhas, A. S. et al. The role of sex and inflammation in cardiovascular outcomes and mortality in COVID-19. Int. J. Cardiol. 337, 127–131 (2021).
Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461–1467 (2022).
Tenforde, M. W. et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020. MMWR Morb. Mortal Wkly Rep. 69, 993–998 (2020).
Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
Zaim, S., Chong, J. H., Sankaranarayanan, V. & Harky, A. COVID-19 and multiorgan response. Curr. Probl. Cardiol. 45, 100618 (2020).
Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880 (2021).
Wong, K. et al. COVID-19 associated vasculitis: a systematic review of case reports and case series. Ann. Med. Surg. 74, 103249 (2022).
Long, B., Brady, W. J., Koyfman, A. & Gottlieb, M. Cardiovascular complications in COVID-19. Am. J. Emerg. Med. 38, 1504–1507 (2020).
Luo, W., Liu, X., Bao, K. & Huang, C. Ischemic stroke associated with COVID-19: a systematic review and meta-analysis. J. Neurol. 269, 1731–1740 (2022).
World Health Organization. A clinical case definition of post-COVID-19 condition by a Delphi consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2021).
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022). This unique article utilized a large national database to highlight the heightened risk of several cardiovascular complications following COVID-19 infection, which helps frame the importance of a solid knowledge base in this topic for healthcare providers.
Gluckman, T. J.et al. 2022 ACC Expert Consensus Decision Pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 79, 1717–1756 (2022). This important expert consensus document discusses different phenotypes of post-COVID-19 condition cardiovascular disease and provides recommendations on screening for myocardial involvement.
Khan, M. S. et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 18, 403 (2020).
Chimenti, C. et al. Intramyocyte detection of Epstein–Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation 110, 3534–3539 (2004).
Deumer, U.-S. et al. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): an overview. J. Clin. Med. 10, 4786 (2021).
Zheng, Y. -Y., Ma, Y. -T., Zhang, J. -Y. & Xie, X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 17, 259–260 (2020).
Raman, B., Bluemke, D. A., Lüscher, T. F. & Neubauer, S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43, 1157–1172 (2022).
Bonaventura, A. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 21, 319–329 (2021).
Beyerstedt, S., Casaro, E. B. & Rangel, É. B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 40, 905–919 (2021).
Pretorius, E. et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 20, 172 (2021).
Osiaevi, I. et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis 26, 53–61 (2023).
Patel, M. A. et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol. Med. 28, 122 (2022).
Proal, A. D. & VanElzakker, M. B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 12, 698169 (2021).
Naveed, Z. et al. Association of COVID-19 infection with incident diabetes. JAMA Netw Open 6, e238866 (2023).
Mohiuddin Chowdhury, A. T. M. et al. Clinical characteristics and the long-term post-recovery manifestations of the COVID-19 patients—a prospective multicenter cross-sectional study. Front. Med. 8, 663670 (2021).
Gyöngyösi, M. et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc. Res. 119, 336–356 (2023). This is a thorough Scientific Statement describing long COVID epidemiology, diagnosis, pathophysiology, and management with specific emphasis on the cardiovascular system.
Miglis, M. G. et al. A case report of postural tachycardia syndrome after COVID-19. Clin. Auton. Res. 30, 449–451 (2020).
Kanjwal, K., Jamal, S., Kichloo, A. & Grubb, B. P. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J. Innov. Card. Rhythm Manag. 11, 4302–4304 (2020).
Ishibashi, Y., Yoneyama, K., Tsuchida, T. & Akashi, J. Y. Post-COVID-19 postural orthostatic tachycardia syndrome. Intern. Med. 60, 2345 (2021).
O’Sullivan, J. S., Lyne, A. & Vaughan, C. J. COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine. BMJ Case Rep. 14, e243585 (2021).
Schofield, J. R. Persistent antiphospholipid antibodies, mast cell activation syndrome, postural orthostatic tachycardia syndrome and post-COVID syndrome: 1 year on. Eur. J. Case Rep. Intern. Med. 8, 002378 (2021).
Johansson, M. et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 3, 573–580 (2021).
Blitshteyn, S. & Whitelaw, S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol. Res. 69, 205–211 (2021).
Bosco, J. & Titano, R. Severe post-COVID-19 dysautonomia: a case report. BMC Infect. Dis. 22, 214 (2022).
Wallukat, G. et al. Functional autoantibodies against G-protein-coupled receptors in patients with persistent long-COVID-19 symptoms. J. Transl. Autoimmun. 4, 100100 (2021).
Buoite Stella, A. et al. Autonomic dysfunction in post-COVID patients with and witfhout neurological symptoms: a prospective multidomain observational study. J. Neurol. 269, 587–596 (2022).
Shouman, K. et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin. Auton. Res. 31, 385–394 (2021).
Campen, C. L. M. C., van, Rowe, P. C. & Visser, F. C. Orthostatic symptoms and reductions in cerebral blood flow in long-haul COVID-19 patients: similarities with myalgic encephalomyelitis/chronic fatigue syndrome. Medicina 58, 28 (2021).
Novak, P. et al. Multisystem involvement in post-acute sequelae of coronavirus disease 19. Ann. Neurol. 91, 367–379 (2022).
Jamal, S. M. et al. Prospective evaluation of autonomic dysfunction in post-acute sequela of COVID-19. J. Am. Coll. Cardiol. 79, 2325–2330 (2022).
Eldokla, A. M. & Ali, S. T. Autonomic function testing in long-COVID syndrome patients with orthostatic intolerance. Auton. Neurosci. 241, 102997 (2022).
Campen, C. L. M. Cvan & Visser, F. C. Long-haul COVID patients: prevalence of POTS are reduced but cerebral blood flow abnormalities remain abnormal with longer disease duration. Healthcare 10, 2105 (2022).
Kwan, A. C. et al. Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection. Nat. Cardiovasc. Res. 1, 1187–1194 (2022).
Chung, T. H. & Azar, A. Autonomic nerve involvement in post-acute sequelae of SARS-CoV-2 syndrome (PASC). J. Clin. Med. 12, 73 (2022).
Eslami, M. et al. Postural orthostatic tachycardia syndrome and orthostatic hypotension post COVID-19. Infect. Disord. Drug Targets 23, e100622205846 (2023).
Hira, R. et al. Objective hemodynamic cardiovascular autonomic abnormalities in post-acute sequelae of COVID-19. Can. J. Cardiol. 39, 767–775 (2023).
Zanin, A. et al. Parasympathetic autonomic dysfunction is more often evidenced than sympathetic autonomic dysfunction in fluctuating and polymorphic symptoms of ‘long-COVID’ patients. Sci. Rep. 13, 8251 (2023).
González-Hermosillo G, J. A. et al. Exaggerated blood pressure elevation in response to orthostatic challenge, a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization. Auton. Neurosci. 247, 103094 (2023).
Chen, X. C. et al. Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease. Am. J. Cardiol. 69, 755–760 (1992).
Pavri, B. B., Ruskin, J. N. & Brooks, R. The yield of head-up tilt testing is not significantly increased by repeating the baseline test. Clin. Cardiol. 19, 494–496 (1996).
Lamarre-Cliche, M. & Cusson, J. The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance. CMAJ 164, 372–376 (2001).
Abbate, G. et al. Postural orthostatic tachycardia syndrome after COVID-19: a systematic review of therapeutic interventions. J. Cardiovasc. Pharmacol. 82, 23–31 (2023).
Low, P. A. et al. Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure. J. Auton. Nerv. Syst. 50, 181–188 (1994).
Goldstein, D. S. et al. Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes. Circulation 106, 2358–2365 (2002).
Bonyhay, I. & Freeman, R. Sympathetic nerve activity in response to hypotensive stress in the postural tachycardia syndrome. Circulation 110, 3193–3198 (2004).
Peltier, A. C. et al. Distal sudomotor findings in postural tachycardia syndrome. Clin. Auton. Res. 20, 93–99 (2010).
Jacob, G. et al. Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance. Circulation 99, 1706–1712 (1999).
Haensch, C.-A., Tosch, M., Katona, I., Weis, J. & Isenmann, S. Small-fiber neuropathy with cardiac denervation in postural tachycardia syndrome. Muscle Nerve 50, 956–961 (2014).
Goldstein, D. S. et al. Neurocirculatory abnormalities in chronic orthostatic intolerance. Circulation 111, 839–845 (2005).
Muenter Swift, N., Charkoudian, N., Dotson, R. M., Suarez, G. A. & Low, P. A. Baroreflex control of muscle sympathetic nerve activity in postural orthostatic tachycardia syndrome. Am. J. Physiol. Heart. Circ. Physiol. 289, H1226–H1233 (2005).
Garland, E. M., Raj, S. R., Black, B. K., Harris, P. A. & Robertson, D. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology 69, 790–798 (2007).
Joseph, P. et al. Insights from invasive cardiopulmonary exercise testing of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Chest 160, 642–651 (2021).
Shah, B. et al. Heart rate variability as a marker of cardiovascular dysautonomia in post-COVID-19 syndrome using artificial intelligence. Indian Pacing Electrophysiol. J. 22, 70–76 (2022).
Marques, K. C., Quaresma, J. A. S. & Falcão, L. F. M. Cardiovascular autonomic dysfunction in ‘Long COVID’: pathophysiology, heart rate variability, and inflammatory markers. Front. Cardiovasc. Med. 10, 1256512 (2023).
NIH National Library of Medicine. ClinicalTrials.gov. Efficacy and safety study of efgartigimod in adults with post-COVID-19 POTS. https://clinicaltrials.gov/ct2/show/NCT05633407
Lala, A. et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J. Am. Coll. Cardiol. 76, 533–546 (2020).
Kini, A. et al. Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur. Heart J. Qual. Care Clin. Outcomes 7, 438–446 (2021).
Metkus, T. S. et al. Myocardial Injury in severe COVID-19 compared with non-COVID-19 acute respiratory distress syndrome. Circulation 143, 553–565 (2021).
Giustino, G. et al. Characterization of myocardial injury in patients with COVID-19. J. Am. Coll. Cardiol. 76, 2043–2055 (2020).
Minhas, A. S. et al. Myocardial work efficiency, a novel measure of myocardial dysfunction, is reduced in COVID-19 patients and associated with in-hospital mortality. Front. Cardiovasc. Med. 8, 667721 (2021).
Deitelzweig, S. et al. Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study. J. Thromb. Thrombolysis 53, 766–776 (2022).
Wei, Z.-Y., Geng, Y.-J., Huang, J. & Qian, H.-Y. Pathogenesis and management of myocardial injury in coronavirus disease 2019. Eur. J. Heart Fail. 22, 1994–2006 (2020).
Petersen, S. E. et al. Cardiovascular magnetic resonance for patients with COVID-19. JACC Cardiovasc. Imaging 15, 685–699 (2022).
Goerlich, E. et al. Multimodality imaging for cardiac evaluation in patients with COVID-19. Curr. Cardiol. Rep. 23, 44 (2021).
Kravchenko, D. et al. Cardiac MRI in patients with prolonged cardiorespiratory symptoms after mild to moderate COVID-19. Radiology 301, E419–E425 (2021).
Puntmann, V. O. et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 28, 2117–2123 (2022).
Artico, J. et al. Myocardial involvement after hospitalization for COVID-19 complicated by troponin elevation: a prospective, multicenter, observational study. Circulation 147, 364–374 (2023).
Giustino, G. et al. Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC Focus Seminar. J. Am. Coll. Cardiol. 76, 2011–2023 (2020). This paper outlines in great detail the mechanisms of myocardial injury in COVID-19 and discusses the clinical impact of these complications.
Cooper, L. T. Myocarditis. N. Engl. J. Med. 360, 1526–1538 (2009).
Trachtenberg, B. H. & Hare, J. M. Inflammatory cardiomyopathic syndromes. Circ. Res. 121, 803–818 (2017).
Friedrich, M. G. et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J. Am. Coll. Cardiol. 53, 1475–1487 (2009).
Aretz, H. T. et al. Myocarditis. A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1, 3–14 (1987).
Caforio, A. L. P. et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 34, 2636–2648, 2648a–2648d (2013).
Boehmer, T. K. et al. Association between COVID-19 and myocarditis using hospital-based administrative data – United States, March 2020–January 2021. MMWR Morb. Mortal. Wkly Rep. 70, 1228–1232 (2021).
Halushka, M. K. & Vander Heide, R. S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc. Pathol. 50, 107300 (2021).
Patel, P. et al. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review. JAMA Netw. Open 4, e2126456 (2021).
Centers for Disease Control and Prevention (CDC). Multisystem Inflammatory Syndrome in Adults (MIS-A) Case Definition and Information for Healthcare Providers (2023).
Rajpal, S. et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 6, 116–118 (2021).
Clark, D. E. et al. Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case-control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC). J. Cardiovasc. Magn. Reson. 23, 106 (2021).
Peretto, G. et al. Ventricular arrhythmias in myocarditis: characterization and relationships with myocardial inflammation. J. Am. Coll. Cardiol. 75, 1046–1057 (2020).
Isakadze, N. et al. C-reactive protein elevation is associated With QTc interval prolongation in patients hospitalized with COVID-19. Front. Cardiovasc. Med. 9, 866146 (2022).
Ruberg, F. L. et al. Utilization of cardiovascular magnetic resonance (CMR) imaging for resumption of athletic activities following COVID-19 infection: an expert consensus document on behalf of the American Heart Association Council on Cardiovascular Radiology and Intervention (CVRI) Leadership and endorsed by the Society for Cardiovascular Magnetic Resonance (SCMR). J. Cardiovasc. Magn. Reson. 24, 73 (2022).
Hendren, N. S., Grodin, J. L. & Drazner, M. H. Unique patterns of cardiovascular involvement in coronavirus disease-2019. J. Card. Fail. 26, 466–469 (2020).
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263–e421 (2022).
Satoskar, M. A. et al. Improving risk prediction for pulmonary embolism in COVID-19 patients using echocardiography. Pulm. Circ. 12, e12036 (2022).
Coromilas, E. J. et al. Worldwide survey of COVID-19-associated arrhythmias. Circ. Arrhythm. Electrophysiol. 14, e009458 (2021).
Desai, A. D., Boursiquot, B. C., Melki, L. & Wan, E. Y. Management of arrhythmias associated with COVID-19. Curr. Cardiol. Rep. 23, 2 (2020).
Driggin, E. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J. Am. Coll. Cardiol. 75, 2352–2371 (2020).
Goerlich, E. et al. Left atrial function in patients with coronavirus disease 2019 and its association with incident atrial fibrillation/flutter. J. Am. Soc. Echocardiogr. 34, 1106–1109 (2021).
Dixit, N. M., Churchill, A., Nsair, A. & Hsu, J. J. Post-acute COVID-19 syndrome and the cardiovascular system: what is known? Am. Heart J. Plus 5, 100025 (2021).
Musikantow, D. R. et al. Atrial fibrillation in patients hospitalized with COVID-19: incidence, predictors, outcomes, and comparison to influenza. JACC Clin. Electrophysiol. 7, 1120–1130 (2021).
Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259–264 (2021).
Huseynov, A., Akin, I., Duerschmied, D. & Scharf, R. E. Cardiac arrhythmias in post-COVID syndrome: prevalence, pathology, diagnosis, and treatment. Viruses 15, 389 (2023).
Ingul, C. B. et al. Cardiac dysfunction and arrhythmias 3 months after hospitalization for COVID-19. J. Am. Heart Assoc. 11, e023473 (2022).
National Institute for Health and Care Excellence. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NICE, 2021).
Centers for Disease Control and Prevention (CDC). Treatment of ME/CFS | Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) (2021).
Wright, J., Astill, S. L. & Sivan, M. The relationship between physical activity and long COVID: a cross-sectional study. Int. J. Environ. Res. Public Health 19, 5093 (2022).
Olshansky, B. et al. Postural orthostatic tachycardia syndrome (POTS): a critical assessment. Prog. Cardiovasc. Dis. 63, 263–270 (2020).
Yancy, C. W. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136, e137–e161 (2017).
Gulati, M. et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 144, e368–e454 (2021).
Collet, J.-P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289–1367 (2021).
Leitman, M. et al. The effect of hyperbaric oxygen therapy on myocardial function in post-COVID-19 syndrome patients: a randomized controlled trial. Sci. Rep. 13, 9473 (2023).
Forshaw, D. et al. STIMULATE-ICP: a pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol. PLoS ONE 18, e0272472 (2023).
Du, Y., Zhang, J., Wu, L. J., Zhang, Q. & Wang, Y. X. The epidemiology, diagnosis and prognosis of long-COVID. Biomed. Environ. Sci. 35, 1133–1139 (2022).
Han, Q., Zheng, B., Daines, L. & Sheikh, A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens 11, 269 (2022).
Peluso, M. J. et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann. Neurol. 91, 772–781 (2022).
Galán, M. et al. Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front. Immunol. 13, 848886 (2022).
Esfandyarpour, R., Kashi, A., Nemat-Gorgani, M., Wilhelmy, J. & Davis, R. W. A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Proc. Natl Acad. Sci. USA 116, 10250–10257 (2019).
Xie, Y., Choi, T. & Al-Aly, Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern. Med. 183, 554–564 (2023).
Xie, Y., Choi, T. & Al-Aly, Z. Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study. BMJ 381, e074572 (2023).
|
Sources 2/ https://www.nature.com/articles/s44161-023-00414-8 The mention sources can contact us to remove/changing this article |
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
 |
 |
 |
